RegenXBio (RB0) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RB0 Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

RegenXBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RB0 Stock 12 Month Forecast

Average Price Target

€21.91

▲(164.98% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for RegenXBio in the last 3 months. The average price target is €21.91 with a high forecast of €39.02 and a low forecast of €8.67. The average price target represents a 164.98% change from the last price of €8.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","40":"€40","13.75":"€13.75","22.5":"€22.5","31.25":"€31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.0199572,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€39.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.914238589090907,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6711016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.75,22.5,31.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.664,10.99907363076923,13.334147261538462,15.669220892307692,18.004294523076922,20.339368153846152,22.674441784615382,25.009515415384612,27.344589046153843,29.679662676923073,32.0147363076923,34.34980993846153,36.68488356923077,{"y":39.0199572,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.664,9.683249122237761,10.702498244475525,11.721747366713286,12.740996488951048,13.76024561118881,14.77949473342657,15.798743855664334,16.817992977902094,17.837242100139857,18.85649122237762,19.87574034461538,20.894989466853144,{"y":21.914238589090907,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.664,8.664546276923076,8.665092553846154,8.66563883076923,8.666185107692307,8.666731384615385,8.667277661538462,8.667823938461538,8.668370215384614,8.668916492307693,8.669462769230769,8.670009046153845,8.670555323076924,{"y":8.6711016,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.054,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.664,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€39.02

Average Price Target€21.91

Lowest Price Target€8.67

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Maughan

Clear Street

€39.02

Buy

371.83%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: CareDx (NASDAQ: CDNA) and RegenXBio (NASDAQ: RGNX)

Mara Goldstein

Mizuho Securities

€39.02

Buy

371.83%

Upside

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Yi Chen

H.C. Wainwright

€22.54

Buy

172.61%

Upside

Reiterated

07/01/26

RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target

Annabel Samimy

Stifel Nicolaus

€36.42

Buy

340.37%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Cronos Group (NASDAQ: CRON) and Boston Scientific (NYSE: BSX)

Judah Frommer

Morgan Stanley

€13.87

Buy

67.76%

Upside

Reiterated

06/24/26

RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained

Brian Skorney

Robert W. Baird

€23.41→€27.75

Buy

235.52%

Upside

Reiterated

06/23/26

Regenxbio price target raised to $32 from $27 at BairdRegenxbio price target raised to $32 from $27 at Baird

Eliana Merle

Barclays

€10.41

Buy

25.82%

Upside

Reiterated

05/15/26

RegenXBio (RGNX) Receives a Buy from Barclays

Mani Foroohar

Leerink Partners

€15.61→€14.74

Buy

78.25%

Upside

Reiterated

05/15/26

RegenXBio (RGNX) Gets a Buy from Leerink Partners

Paul Choi

Goldman Sachs

€10.41→€8.67

Hold

4.85%

Upside

Reiterated

05/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (NASDAQ: RGNX), Align Tech (NASDAQ: ALGN) and Keros Therapeutics (NASDAQ: KROS)

Alec Stranahan

Bank of America Securities

€21.68→€12.14

Buy

46.79%

Upside

Reiterated

05/14/26

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)

Luca Issi

RBC Capital

€16.48

Buy

99.22%

Upside

Reiterated

05/14/26

RegenXBio (RGNX) Gets a Buy from RBC Capital

Daniil Gataulin

Chardan Capital

€45.09

Buy

445.22%

Upside

Reiterated

01/28/26

Chardan Capital Remains a Buy on RegenXBio (RGNX)

Sean McCutcheon

Raymond James

€25.15

Buy

204.07%

Upside

Reiterated

09/05/25

RegenXBio (RGNX) Receives a Buy from Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Maughan

Clear Street

€39.02

Buy

371.83%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: CareDx (NASDAQ: CDNA) and RegenXBio (NASDAQ: RGNX)

Mara Goldstein

Mizuho Securities

€39.02

Buy

371.83%

Upside

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Yi Chen

H.C. Wainwright

€22.54

Buy

172.61%

Upside

Reiterated

07/01/26

RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target

Annabel Samimy

Stifel Nicolaus

€36.42

Buy

340.37%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Cronos Group (NASDAQ: CRON) and Boston Scientific (NYSE: BSX)

Judah Frommer

Morgan Stanley

€13.87

Buy

67.76%

Upside

Reiterated

06/24/26

RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained

Brian Skorney

Robert W. Baird

€23.41→€27.75

Buy

235.52%

Upside

Reiterated

06/23/26

Regenxbio price target raised to $32 from $27 at BairdRegenxbio price target raised to $32 from $27 at Baird

Eliana Merle

Barclays

€10.41

Buy

25.82%

Upside

Reiterated

05/15/26

RegenXBio (RGNX) Receives a Buy from Barclays

Mani Foroohar

Leerink Partners

€15.61→€14.74

Buy

78.25%

Upside

Reiterated

05/15/26

RegenXBio (RGNX) Gets a Buy from Leerink Partners

Paul Choi

Goldman Sachs

€10.41→€8.67

Hold

4.85%

Upside

Reiterated

05/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (NASDAQ: RGNX), Align Tech (NASDAQ: ALGN) and Keros Therapeutics (NASDAQ: KROS)

Alec Stranahan

Bank of America Securities

€21.68→€12.14

Buy

46.79%

Upside

Reiterated

05/14/26

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)

Luca Issi

RBC Capital

€16.48

Buy

99.22%

Upside

Reiterated

05/14/26

RegenXBio (RGNX) Gets a Buy from RBC Capital

Daniil Gataulin

Chardan Capital

€45.09

Buy

445.22%

Upside

Reiterated

01/28/26

Chardan Capital Remains a Buy on RegenXBio (RGNX)

Sean McCutcheon

Raymond James

€25.15

Buy

204.07%

Upside

Reiterated

09/05/25

RegenXBio (RGNX) Receives a Buy from Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RegenXBio

3 Months

Judah FrommerMorgan Stanley

Success Rate

9/15 ratings generated profit

Average Return

+11.28%

Copying Judah Frommer's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +11.28% per trade.

1 Year

Judah FrommerMorgan Stanley

Success Rate

10/15 ratings generated profit

Average Return

+15.77%

Copying Judah Frommer's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +15.77% per trade.

2 Years

Judah FrommerMorgan Stanley

Success Rate

10/15 ratings generated profit

Average Return

+14.83%

Copying Judah Frommer's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RB0 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RB0 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RB0 average Analyst price target in the past 3 months is 21.91.

Each month's total comprises the sum of three months' worth of ratings.

RB0 Financial Forecast

RB0 Earnings Forecast

Next quarter’s earnings estimate for RB0 is €0.07 with a range of -€1.07 to €0.63. The previous quarter’s EPS was -€1.49. RB0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year RB0 has Performed in-line its overall industry.

RB0 Sales Forecast

Next quarter’s sales forecast for RB0 is €84.80M with a range of €19.11M to €112.48M. The previous quarter’s sales results were €5.55M. RB0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year RB0 has Performed in-line its overall industry.

RB0 Stock Forecast FAQ

What is DE:RB0’s average 12-month price target, according to analysts?

Based on analyst ratings, RegenXBio’s 12-month average price target is 21.91.

What is DE:RB0’s upside potential, based on the analysts’ average price target?

RegenXBio has 164.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RegenXBio a Buy, Sell or Hold?

RegenXBio has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is RegenXBio’s share price target?

The average share price target for RegenXBio is 21.91. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €39.02 ,and the lowest forecast is €8.67. The average share price target represents 164.98% Increase from the current price of €8.27.

What do analysts say about RegenXBio?

RegenXBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of RegenXBio?

To buy shares of DE:RB0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

RegenXBio (RB0) Stock Forecast & Price Target

RB0 Analyst Ratings

RB0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RegenXBio

RB0 Analyst Recommendation Trends

RB0 Financial Forecast

RB0 Earnings Forecast

RB0 Sales Forecast

RB0 Stock Forecast FAQ

Detailed List of Analyst Forecasts